Q-omics provides the consensus-scored OCIAD2 profile across patient tissues and cancer cell-line models. OCIAD2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, OCIAD2 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, OCIAD2 RNA expression shows 19,202 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight KIRP, HNSC, and KICH as cancer lineages where OCIAD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OCIAD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OCIAD2 survival associations across molecular data types. OCIAD2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OCIAD2 RNA expression–survival associations across cancer types. High OCIAD2 expression shows unfavorable associations in HNSC and LGG, but favorable associations in KIRP, UCEC, OV and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for OCIAD2 RNA expression.
This table summarizes OCIAD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for OCIAD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OCIAD2 shows higher tumor expression in HNSC, BLCA, KIRC, THCA, COAD and LUAD. The HNSC box plot shows higher OCIAD2 RNA expression in tumor versus normal tissue (log2 FC = +2.017, t-test p < 0.001).
This table shows molecular features associated with OCIAD2 in patient tissues and cancer cell lines. In patient samples, OCIAD2 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set. In cancer cell lines, OCIAD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
